MedPath

EFFECTIVENESS OF ALBENDAZOL IN RELATION TO METRONIDAZOL IN THE TREATMENT OF GIARDIASIS IN SCHOOLS OF THE DISTRICT OF BELEN 2009

Not Applicable
Conditions
-A071 Giardiasis [lambliasis]
Giardiasis [lambliasis]
A071
Registration Number
PER-136-09
Lead Sponsor
ASOCIACION CIVIL SELVA AMAZONICA, Universidad McGill, Canada,
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Not specified
Target Recruitment
286
Inclusion Criteria

• Primary school students belonging to the Educational Institutions of the Bethlehem District.
• School boys and girls.
• Positive diagnosis for Giardia duodenalis by coproparasitological analysis.
• Informed consent signature of the parents or legal guardians of the students under study according to the Helsinki declaration.
• Child´s consent confirming their willingness to participate in the study

Exclusion Criteria

• School children who do not voluntarily settle their participation in the study or whose parents or guardians do not sign the necessary informed consent for participation in the study.
• Having received treatment against Giardia duodenalis or against intestinal helminths within 7 days prior to the start of the study.
• Negative diagnosis for Giardia duodenalis

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<br>Outcome name:Efficacy will be measured by the clinical examination performed for five consecutive days.<br>Measure:Efficacy level<br>Timepoints:5 days<br>
Secondary Outcome Measures
NameTimeMethod
<br>Outcome name:Prevalence will be measured by clinical examination and<br>  laboratory tests performed for five consecutive days.<br>Measure:Level of prevalence of Giardiasis in primary school students of the Bethlehem district.<br>Timepoints:During treatment<br>;<br>Outcome name:Record of adverse reactions occurred during the study.<br>Measure:Emergence of adverse reactions<br>Timepoints:During the study<br>
© Copyright 2025. All Rights Reserved by MedPath